¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÀåÇÐȸ 2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽÉÀåÇÐȸ 2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-19
±³À°ÀÏÀÚ : 2024-04-19
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ (HICO)

±³À°ÁÖÁ¦ : 2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  

À̸ÞÀÏ : herz8@circulation.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ÀÇ»çÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÁ¤Ã¥

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 49 ½Ã°£ 15ºÐ

¼¼ºÎ¼ö°­·á : 150,000¿ø  

ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ 120000 / ÀüÀÓÀÇ,Àü°øÀÇ,±âŸ 70000ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ 150000 / ÀüÀÓÀÇ,Àü°øÀÇ,±âŸ 90000


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 09:30~09:50 Lipid lowering with vascular image guided rather than blood markers : We have evidences and support it Sang Eun Lee(Ewha Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 09:50~10:10 Lipid lowering with vascular image guided rather than blood markers : It has limitation and do not  support it Woohyeun Kim(Hanyang Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 10:10~10:30 TG Is Therapeutic target:  We have evidences and support it B©ªrge Nordestgaard(University of Copenhagen Denmark)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 10:30~10:50 TG Is Therapeutic target: It has limitations and does not  support it Nam Hoon Kim(Korea Univ. Korea)

Åä·Ð 04¿ù 19ÀÏ 102È£ 10:50~11:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 11:10~11:30 Obesity, How to Define and Any Type? ¿À»ó¿ì(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 11:30~11:50 Obesity and Cardiovascular Complication Àü°æÇö(Àϻ꺴¿ø)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 11:50~12:10 Brand New Drug for Obesity and Their Clinical Implication ¹Ú»ó¹Î(À»ÁöÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 12:10~12:30 Diet Intervention for Obesity È«¿©Áø(°í·ÁÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 102È£ 12:30~12:40 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 12:45~13:05 Evidence-based Approach to Combination Therapy Focused on Intensive BP Lowering ÃÖÁ¤Çö(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 13:05~13:25 A Paradigm Shift in Dyslipidemia Treatment ±èÁøÈ£(ÇѾçÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 102È£ 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 14:30~14:45 Invasive and Non-invasive Coronary Imaging for Vulnerable Plaque: Is It Sufficent or Validated? Çã½ÂÈ£(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 14:45~15:00 Overwhelming Trials of Imaging-Guided PCI: What Are Still Unmet Needs? ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 15:00~15:15 OMT Sufficent for Vulnerable Plaque È«¼ºÁø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 15:15~15:30 Preventive PCI for Vulnerable Plaque ¾ÈÁ¤¹Î(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 102È£ 15:30~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 16:10~16:25 ASD Closure: Plan, Sizing, Device Selection °­¿õö(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 16:25~16:40 PFO Closure: Plan, Sizing, Device Selection ÀÌÇöÁ¾(¼¼Á¾º´¿ø)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 16:40~16:55 LAA Closure: Plan, Sizing, Device Selection ±èÁß¼±(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 102È£ 16:55~17:10 ICE Use during Procedure: Expert Case-Based Skills ÀÓÈ«ÀÇ(ÇѸ²ÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 102È£ 17:10~17:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 09:30~09:50 Recent Updates on SGLT2i Trials À±Á¾Âù(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 09:50~10:10 Recent Updates on Ferric Carboxymaltose Trials À̼±±â(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 10:10~10:30 Recent Updates on LVAD & HTx Trials ÇöÁØÈ£(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 10:30~10:50 Recent Updates on AI in HF Trials À±¹ÎÀç(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 103È£ 10:50~11:00 Panel Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 11:10~11:30 Interatrial Shunt Device: Is there still Hope? Finn Gustafsson(Rigshospitalet-Copenhagen University Hospital Denmark)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 11:30~11:50 Natriuretic Peptide Receptor 1 Agonist: Mechanism and Future Perspectives Hae-Young Lee(Seoul National Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 11:50~12:10 Inhibition of Protein Phosphatase 1 in Heart Failure Sang Eun Lee(Ulsan Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 12:10~12:30 Acoramidis: New Weapon for ATTR-CM Darae Kim(Sungkyunkwan Univ. Korea)

Åä·Ð 04¿ù 19ÀÏ 103È£ 12:30~12:40 Panel Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 12:45~13:05 The Benefit of Clopidogrel Over Aspirin after DAPT for CAD Patients Undergoing PCI °­ÁöÈÆ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 13:05~13:25 The Current Guidelines for Antithrombotic Therapy in Patients with NVAF Undergoing PCI À̽ÂÁØ(¿¬¼¼ÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 103È£ 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 14:30~14:50 Proper Measurement of Office BP in the Era of Non Mercury Sphygmomanometer ÀÌÀº¹Ì(¿ø±¤ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 14:50~15:10 The Use of ABPM for the Diagnosis and Treatment of Hypertension ¹ÚÀçÇü(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 15:10~15:30 Latest Update on Application of Home BP for Management of Hypertension À̹«¿ë(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 15:30~15:50 Validation of Cuffless BP Monitoring Device ÀÌÇØ¿µ(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 103È£ 15:50~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 16:10~16:30 Historical review of hypertension definition and management: Reappraisal of the past concept À念¿ì(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 16:30~16:50 BP, the lower, the better irrespective of antihypertensive agent use À§Áø(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 16:50~17:10 Lower BP in some inflection is harmful irrespective of antihypertensive agent  use ¼­Àçºó(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 103È£ 17:10~17:30 Deep meditation on Low DBP focused of J curve in DBP ±èº´½Ä(ÇѾçÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 103È£ 17:30~17:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 09:30~09:50 ´ç´¢°ü·Ã ½ÉÀåÁúȯ ±èÇü±Ô(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 09:50~10:10 ¹ÌÅäÄܵ帮¾Æ¿Í ½ÉÀåÁúȯ ÀåÀºÈ­(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 10:10~10:30 ½ÉÇ÷°ü¿¬±¸¸¦ À§ÇÑ Á¶Á÷°øÇÐ ¹ÚÇöÁö(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 10:30~10:50 Ç÷°ü¿°Áõ ¹ÚÁ¾±æ(Çѱ¹»ý¸í°øÇבּ¸¿ø ¹ÙÀÌ¿À½Å¾àÁß°³¿¬±¸¼¾ÅÍ)

Åä·Ð 04¿ù 19ÀÏ 105È£ 10:50~11:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 11:10~11:30 ºÎÁ¤¸ÆÄ¡·á¸¦ À§ÇÑ ±âÃÊ¿¬±¸ À±¼Ò¹Ì(Àü³²´ëÇб³)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 11:30~11:50 ½ÉÀåÀ̽Ä, ÀÌÁ¾Àå±âÀÌ½Ä Á¤Àμ®(Àü³²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 11:50~12:10 Çü»ó±â¿ª Ç÷°ü µð¹ÙÀ̽º ¼ºÇÐÁØ(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 12:10~12:30 ÀΰøÇ÷°ü ±¸±³ÀÎ(¿ï»ê´ëÇб³)

Åä·Ð 04¿ù 19ÀÏ 105È£ 12:30~12:40 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 12:45~13:05 How to Reach LDL-C Target Goal: Benefits of Atorvastatin/Ezetimibe Combination ¹®µ¿±Ô(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 13:05~13:25 Strategy for Reducing the Risk of Stroke in HTN Patients with LVH Á¶ÁØȯ(Áß¾ÓÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 105È£ 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 14:30~14:50 Acute Coronary Syndrome in ACHD ¼ÛÁø¿µ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 14:50~15:10 Aortic Dissection in ACHD ¼­Áö¿ø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 15:10~15:30 Syncope in ACHD ½ÉÀç¹Î(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 15:30~15:50 GI Bleeding in ACHD Á¤¼¼¿ë(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 105È£ 15:50~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 16:10~16:30 Fontan Physiology and Good Fontan in ACHD Alexander Van De Bruaene(University Hospitals Leuven Belgium)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 16:30~16:50 Fontan Failure and Heart Failure in ACHD Alexander Van De Bruaene(University Hospitals Leuven Belgium)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 16:50~17:10 Ventricle Functional Assessment by CMR in Adult with Fontan Physiology Yoonseong Lee(Seoul National Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 105È£ 17:10~17:30 Changes in Physical Performance after Fontan in Adult Patients Woong-Han Kim(Seoul National Univ. Korea)

Åä·Ð 04¿ù 19ÀÏ 105È£ 17:30~17:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 09:30~09:50 Current Update in AMI Management Using Digital Health Àü±âÇö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 09:50~10:10 What's New in Reperfusion Therapy to Minimize Infact Size ÀÌÀåÈÆ(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 10:10~10:30 Hemodynamic Support in AMI with Cardiogenic Shock: What's New Evidence? ¾çÁ¤ÈÆ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 10:30~10:50 How to Manage out-of Hospital Cardiac Arrest after AMI ¿ìÁ¾½Å(°æÈñÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 202È£ 10:50~11:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 11:10~11:35 Normal Conduction System in Pediatric Hearts °íÁö¿ø(¼­¿ï´ëÇб³)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 11:35~12:00 Conduction Concerns in Congenital Heart Disease for Electrophysiologist ¼Û¹Ì°æ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 12:00~12:25 Conduction Disturbance Associated with Cardiovascular Surgery °ûÀç°Ç(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 12:25~12:40 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 12:45~13:05 Early Initiation of Evolocumab in Patients With Multivessel Disease À念¿ì(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 13:05~13:25 Why Evolocumab? ESC Strategy: Early, Safety, CV Outcomes Àü±âÇö(¼­¿ïÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 202È£ 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 14:30~14:50 Optimal Goal of LDL-C: The Lower, The Better? ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 14:50~15:10 What's new in Korean AMI Guideline for Medical Therapy? ±èÇö±¹(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 15:10~15:30 Cardiac Rehabilitation in the Elderly: The Earlier, The Better? Á¶ÁØȯ(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 15:30~15:50 Surveillance and Follow-up after Revascularization for Multivessel Disease À±¿µÁø(¿¬¼¼¿øÁÖÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 202È£ 15:50~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 16:10~16:30 All about Basic ECG Differences by Sex ¹Ú¿¹¹Î(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 16:30~16:50 QRS Complex for LV Function and Structure ¹Ú°æ¹Î(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 16:50~17:10 Prediction of OCAD with QTc Á¶µ¿Çõ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 202È£ 17:10~17:30 Detection of Peripartum Cardiomyopathy by AI ECG ±ÇÁظí(¼¼Á¾º´¿ø)

Åä·Ð 04¿ù 19ÀÏ 202È£ 17:30~17:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 12:45~13:05 Strategy for Perfect 24hr BP Control; The Role of Azilsartan ÃßÀºÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 13:05~13:25 Intensive Treatment Strategy in Hypertension ±Ç¿À¼º(°¡Å縯ÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 204È£ 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 14:30~14:42 Smartphone-based AI ECG Analyzer 1 Á¶¿µÁø(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 14:42~14:54 Smartphone-based AI ECG Analyzer 2 ±èÁßÈñ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 14:54~15:06 AI in Cardiovascular Imaging 1 ÇÏÈ£Áø(°­¿ø´ëÇб³)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 15:06~15:18 AI in Cardiovascular Imaging 2 ±¸ÇöÁ¤(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 15:18~15:30 Ring-Type Blood Pressure Measurement Device 1 °­½ÃÇõ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 15:30~15:42 Ring-Type Blood Pressure Measurement Device 2 À̺´È¯(Skylabs)

Åä·Ð 04¿ù 19ÀÏ 204È£ 15:42~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 16:10~16:30 Introduction of SCORE2 and SCORE2-ASIA Frank Visseren(University Medical Center Utrecht Netherlands)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 16:30~16:50 Introduction of PREVENT Equations Ju-Mi Lee(Chungnam National Univ.)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 16:50~17:10 KoGES-based CVD Prediction Model Hokyou Lee(Yonsei Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 204È£ 17:10~17:30 Challenges for Asian CVD Risk Prediction Tools Sangwoo Park(Ulsan Univ. Korea)

Åä·Ð 04¿ù 19ÀÏ 204È£ 17:30~17:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 09:30~09:50 Á߾ӽɳúÇ÷°üÁúȯ¼¾ÅÍ ¿î¿µ ¹æÇâ ¹× »ç¾÷¼öÇà °èȹ ÀÌÇØ¿µ(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 205È£ 09:50~10:00 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 10:00~10:20 ±Ç¿ª½É³úÇ÷°üÁúȯ¼¾ÅÍ ±â¹Ý ÀÀ±Þ½É³úÇ÷°üÁúȯ ³×Æ®¿öÅ© ½Ã¹ü»ç¾÷ ÁøÇà »ç·Ê 1 ¹ÚÁ¾¼º(µ¿¾ÆÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 205È£ 10:20~10:30 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 10:30~10:50 ½ÉÇ÷°üÁúȯ ÀÎÀû ³×Æ®¿öÅ© ½Ã¹ü»ç¾÷ ÁøÇà »ç·Ê 2 ¿À¼ºÁø(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø)

Åä·Ð 04¿ù 19ÀÏ 205È£ 10:50~11:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 11:10~11:30 Á¤ºÎÀÇ ½ÉÇ÷°üÁúȯ ¿¹¹æ°ú °ü¸® ÇöȲ: ½É³úÇ÷°üÁúȯÀÇ ¿¹¹æ°ü¸® ÇöȲ°ú ÁÖ¿ä À̽´ ¹× ±¹°¡Åë°èü°è ±¸Ãà»ç¾÷ ¿î¿µ ÇöȲ ±èÇöâ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 205È£ 11:30~11:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 11:40~12:00 ½ÉÇ÷°üÁúȯÀÇ ÇöÀç¿Í ¹Ì·¡-ÁÖ¿ä ¾ÆÁ¨´Ù ¹ßÇ¥ °­ÇöÀç(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 205È£ 12:00~12:10 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 12:10~12:30 °Ç°­ÁõÁø±â±Ý»ç¾÷¿¡¼­ÀÇ ½ÉÇ÷°üÁúȯ ¿¹¹æ°ü¸®»ç¾÷ ÇöȲ°ú ¹®Á¦Á¡ ¿ÕÁÖ¹Ì(½ÉÀåÇבּ¸Àç´Ü)

Åä·Ð 04¿ù 19ÀÏ 205È£ 12:30~12:40 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±âŸ 04¿ù 19ÀÏ 205È£ 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 14:30~15:00 ¿ì¸®³ª¶ó ÀǷẸÇèÁ¦µµ¿Í ¿Ü±¹ ÀǷẸÇèÁ¦µµÀÇ ºñ±³ Áö¿µ°Ç(Â÷ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 15:00~15:30 ¿ì¸®³ª¶ó ½Ç¼Õº¸ÇèÁ¦µµÀÇ ¿î¿µ ¼­Àμ®(´ëÇѺ´¿øÇùȸ)

Åä·Ð 04¿ù 19ÀÏ 205È£ 15:30~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 16:10~16:30 Çù½ÉÁõÀÌ ÁßÁõÁúȯÀÌ ¾Æ´Ñ°¡? ¼­Á¸(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 16:30~16:50 ½ÉºÎÀüÀÌ ÁßÁõÁúȯÀÌ ¾Æ´Ñ°¡? ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 205È£ 16:50~17:10 ÁßÁõ½ÉÀåÁúȯ¿¡ ´ëÇÑ Áö¿ø°­È­¹æÇâ À¯º¸¿µ(º¸°Çº¹ÁöºÎ)

Åä·Ð 04¿ù 19ÀÏ 205È£ 17:10~17:40 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 09:30~09:50 Infective Endocarditis ȲÈñÁ¤(°æÈñÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 09:50~10:10 Hypertrophic Cardiomyopathy À̽ÂÇ¥(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 10:10~10:30 Cardio-oncology À±ÇöÁÖ(Àü³²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 10:30~10:50 Cardiovascular Assessment before Non-cardiac Surgery ÃÖÀÇ¿µ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 300B 10:50~11:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 11:10~11:35 Diastolic Function Jong-Won Ha(Yonsei Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 11:35~12:00 Mitral Regurgitation Jae-Kwan Song(Ulsan Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 12:00~12:25 Thick Myocardium Sangchol Lee(Sungkyunkwan Univ. Korea)

Åä·Ð 04¿ù 19ÀÏ 300B 12:25~12:40 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 12:45~13:05 What Makes ARNI Conerstone among HF 4 Pillar Treatment? ÇÑÁ¤±Ô(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 13:05~13:25 See the Unseen: Forgotten HF Patients ¹ÚÁøÁÖ(¼­¿ïÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 300B 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 14:30~14:55 Cardiovascular Epidemiology Frank Visseren(University Medical Center Utrecht Netherlands)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 14:55~15:20 Electrophysiology Masateru Takigawa(Tokyo Medical & Dental Univ. Japan)

±³À°½Ã°£ 04¿ù 19ÀÏ 300B 15:20~15:45 Heart Failure Finn Gustafsson(Rigshospitalet-Copenhagen University Hospital Denmark)

Åä·Ð 04¿ù 19ÀÏ 300B 15:45~16:00 Discussion ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 09:30~09:50 Bradycardia & pacing ECG ÀÓ¿ìÇö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 09:50~10:10 Narrow QRS complex tachycardia ÀÌ¿µ½Å(°æÈñÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 10:10~10:30 Wide QRS complex tachycardia ¹Ú¿µ¾Æ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 10:30~10:50 Pediatric ECG À±ÀÚ°æ(¼¼Á¾º´¿ø)

Åä·Ð 04¿ù 19ÀÏ 300C 10:50~11:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 11:00~11:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 11:10~11:30 Catheter ablation of atrial fibrillation in patients with HFrEF and HFpEF Hyoung-Seob Park(Keimyung Univ.  Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 11:30~11:50 AV node ablation and conduction system pacing in patients with AF and heart failure Tae-Hoon Kim(Yonsei Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 11:50~12:10 Neuromodulation in AF management: current evidences and future perspectives Seung-Young Roh(Korea Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 12:10~12:30 Clinical utility of impedance monitoring during pulmonary vein isolation for durable lesion formation Masateru Takigawa(Tokyo Medical & Dental Univ Japan)

Åä·Ð 04¿ù 19ÀÏ 300C 12:30~12:40 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 12:40~12:45 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 12:45~13:05 New Clinical Trial of Fimasartan in Korea Hyperpertensive Patient ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 13:05~13:25 Optimal Treatment Strategy for Intensive BP control with Fimasartan Combination Therapy ¿øÈ£¿¬(Áß¾ÓÀÇ´ë)

±âŸ 04¿ù 19ÀÏ 300C 13:25~14:25 Case ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:25~14:30 Break ( )

±âŸ 04¿ù 19ÀÏ 300C 13:30~13:45 ͺ ±è±ââ ±³¼ö´Ô ȸ°í Youngkeun Ahn(Chonnam National Univ. Korea)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 13:45~14:10 Lipid Profile in Clinical Practice 2024 B©ªrge Nordestgaard(University of Copenhagen Danmark)

Åä·Ð 04¿ù 19ÀÏ 300C 14:10~14:20 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 14:20~14:30 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 14:30~14:50 Stylet-driven vs. Lumenless pacing lead for left bundle branch area pacing ÀÌÁöÇö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 14:50~15:10 Ultrasound-guided CIED implantation ȲÁ¾¹Î(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 15:10~15:30 Best strategy during CIED revision or upgrade °ûÇýºó(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 15:30~15:50 Update on CIED remote monitoring ȲÀ¯¹Ì(°¡Å縯ÀÇ´ë)

Åä·Ð 04¿ù 19ÀÏ 300C 15:50~16:00 Discussion ( )

ÈÞ½Ä 04¿ù 19ÀÏ 16:00~16:10 Break ( )

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 16:10~16:40 ÀÇ·áÁ÷¾÷Àü¹®¼º ¹× À±¸®: ÀÇ·á½Ã½ºÅÛ°úÇÐ ±³À°ÀÌ ¿Ö ÇÊ¿äÇÑ°¡? º¯Ã¢¿ì(¹ý¹«¹ýÀÎ ¿ì¸®´©¸®) Çʼö

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 16:40~17:10 ÀÇ·áÀ±¸®¿¡ ÀÔ°¢ÇÑ µðÁöÅÐ ÀÇÇÐÀü¹®Á÷¾÷¼º °³³ä°ú ÀÇ»ç ¼Ò¼È¹Ìµð¾î »ç¿ë °¡À̵å ÀÌÁ¤¿¬(ÀÌÈ­ÀÇ´ë) Çʼö

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 17:10~17:40 Áø·á½Ç¿¡¼­ ¹Ýµå½Ã À¯³äÇØ¾ß ÇÒ ÀÇ·á¹ý À§¹Ý »ç·Êµé or Áø·á½Ç¿¡¼­ÀÇ ÀÇ»çÀÇ ¼³¸íÀǹ« ÀÌ¿µ¹Ì(°í·ÁÀÇ´ë) Çʼö

±³À°½Ã°£ 04¿ù 19ÀÏ 300C 17:40~18:10 Àǻ簡 ¾Ë¾Æ¾ß ÇÒ µµÇιæÁö ±ÝÁö¾à¹° ³ª»óÈÆ(¼­¿ïÀÇ´ë) Çʼö

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÀåÇÐȸ 2024 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦98Â÷ ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ Çмú´ëȸ / 2024³â Ãá°è ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ Çмú´ëȸ in conjunction with International Congress of ORL-HNS 2024(1ÀÏÂ÷) : 2024-04-20
´ÙÀ½±Û ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2024³âµµ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-04-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 0 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 1 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 0 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 1 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 0 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 1 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 0 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 2 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 1 2024-04-29
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 0 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 2 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 5 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 1 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 0 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 0 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷